The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study

Fu, Naikuan; Yang, Shicheng; Zhang, Jing; Zhang, Peng; Liang, Min; Cong, Hongliang; Lin, Wenhua; Tian, Fengshi; Lu, Chengzhi

doi:10.1007/s11255-017-1718-4

Cited by 7 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing numbers of experiments are demonstrating that probucol plays a prophylactic role in the development of CIAKI. In their multicenter randomized controlled trial, Fu et al [11] found that prophylactic administration of probucol in the perioperative period of selective coronary intervention had a certain preventive effect against CIAKI. Yin et al [12] showed that probucol can decrease the incidence of CIAKI in patients at high-risk of CIAKI with acute coronary syndrome undergoing primary or emergency angioplasty (4.2% vs 21.3%, P < .001), and the incidence of cystatin C-based CIAKI was significantly lower in the probucol than control group (29.2% vs 51.9%, respectively; P < .001).…”

Section: Discussionmentioning

confidence: 99%

Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention

Wang

Shi

Xu³

et al. 2019

Medicine

Self Cite

View full text Add to dashboard Cite

Objective: This study was performed to explore the effects of probucol on contrast-induced acute kidney injury (CIAKI) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI). Methods: In total, 220 patients undergoing PCI were randomly assigned to either the control group (hydration from 12 hours before to 12 hours after contrast administration; n = 110) or the probucol group (hydration plus probucol 500 mg twice daily 1 day before and 3 days after the operation; n = 110). The primary endpoint was the occurrence of serum creatinine (Scr)-based CIAKI, defined as an absolute increase in Scr by 0.5 mg/dl (44.2 μmol/L) or a relative 25% increase from baseline within 48 to 72 hours after exposure to contrast medium. The secondary outcomes were composite variations in Scr, blood urea nitrogen (BUN), creatinine clearance rate (Ccr) within 48 to 72 hours, and major adverse events during hospitalization or the 7-day follow-up period after PCI. Results: The overall incidence of Scr-based CIAKI was 7.3% (16/220): 5.5% (6/110) in the control group and 9.1% (10/110) in the probucol group (χ 2 = 1.078, P = .298). There were no significant differences in the occurrence rate of major adverse events during hospitalization or the 7-day follow-up period after PCI between the groups. Multivariate logistic regression analysis showed that probucol was not an independent protective factor for CIAKI (odds ratio, 1.825; 95% confidence interval, 0.639–5.212; P = .261). However, hydration was an independent protective factor (odds ratio, 0.997; 95% confidence interval, 0.995–0.999; P = .004). Conclusion: Probucol cannot effectively reduce the incidence of CIAKI through its anti-inflammatory and antioxidative stress effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention

Wang

Shi

Xu³

et al. 2019

Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…The systematic search identified 556 articles, and a full-text screening was performed for 129 articles. Twenty-eight studies were selected [ 15 – 42 ], including four identified through citation tracking and two performed on pediatric patients [ 24 , 28 ] (Fig. 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…A high heterogeneity between studies was observed ( I 2 = 92.04%, p < 0.0001), and the overall PC-AKI incidence was highly variable (1.5–35.5%), depending on the PC-AKI definition and studied population (Table 2 ). Prophylactic measures included IV hydration [ 15 – 20 , 23 , 24 , 27 , 31 , 42 ], anti-hyperlipidemic drugs [ 15 , 22 , 42 ] and N-acetylcysteine administration [ 18 , 19 , 23 , 27 ], and bicarbonate infusion [ 19 , 20 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol: part 2—intra-arterial administration

et al. 2022

View full text Add to dashboard Cite

Objectives To evaluate the incidence of adverse drug reactions (ADRs), including hypersensitivity reactions (HSRs) and post-contrast acute kidney injury (PC-AKI), after intra-arterial (IA) administration of ioversol. Methods and materials A systematic literature search was performed (1980–2021) and studies documenting IA use of ioversol, and reporting safety outcomes were selected. Key information on study design, patients’ characteristics, indication, dose, and type of safety outcome were extracted. Results Twenty-eight studies (including two pediatric studies) with 8373 patients exposed to IA ioversol were selected. Studies were highly heterogenous in terms of design, PC-AKI definition, and studied population. PC-AKI incidence after coronary angiography was 7.5–21.9% in a general population, 4.0-26.4% in diabetic patients, and 5.5–28.9% in patients with chronic kidney disease (CKD). PC-AKI requiring dialysis was rare and reported mainly in patients with severe CKD. No significant differences in PC-AKI rates were shown in studies comparing different iodinated contrast media (ICM). Based on seven studies of ioversol clinical development, the overall ADR incidence was 1.6%, comparable to that reported with other non-ionic ICM. Pediatric data were scarce with only one study reporting on PC-AKI incidence (12%), and one reporting on ADR incidence (0.09%), both after coronary angiography. Conclusions After ioversol IA administration, PC-AKI incidence was highly variable between studies, likely reflecting the heterogeneity of the included study populations, and appeared comparable to that reported with other ICM. The rate of other ADRs appears to be low. Well-designed studies are needed for a better comparison with other ICM. Key Points • PC-AKI incidence after IA administration of ioversol appears to be comparable to that of other ICM, despite the high variability between studies. • The need for dialysis after IA administration of ioversol is rare. • No obvious difference was found regarding the safety profile of ioversol between IA and IV administration.

show abstract

“…Probucol was initially designed as lipid-lowering drug but was never established in the clinic since it also exhibits HDL-lowering effects. In a randomized controlled trial published this year, Fu et al compared probucol plus hydration with hydration alone in subjects with coronary heart disease undergoing percutaneous coronary intervention [ 17 ]. CIN incidences were 4 versus 10.9%.…”

Section: Other Drugsmentioning

confidence: 99%

Contrast-Induced Nephropathy: Update on the Use of Crystalloids and Pharmacological Measures

Patschan

Buschmann

Ritter

2018

International Journal of Nephrology

View full text Add to dashboard Cite

Contrast-induced nephropathy (CIN) is a frequent and severe complication in subjects receiving iodinated contrast media for diagnostic or therapeutic purposes. Several preventive strategies were evaluated in the past. Recent clinical studies and meta-analyses delivered some new aspects on preventive measures used in the past and present. We will discuss all pharmacological and nonpharmacological procedures. Finally, we will suggest individualized recommendations for CIN prevention.

show abstract

The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study

Abstract: Probucol combined with hydration more effectively decreased the incidence of CIN in patients with coronary heart disease undergoing PCI compared with hydration alone.

Cited by 7 publications

References 27 publications

Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention

Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention

A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol: part 2—intra-arterial administration

Contrast-Induced Nephropathy: Update on the Use of Crystalloids and Pharmacological Measures

Contact Info

Product

Resources

About